Patents by Inventor Thomas Leedom

Thomas Leedom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES
    Publication number: 20250186441
    Abstract: Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need thereof. Methods of modulating glycolate oxidase activity in a human or animal subject are also provided.
    Type: Application
    Filed: December 18, 2024
    Publication date: June 12, 2025
    Inventors: Ayman KABAKIBI, Mehmet KAHRAMAN, Michael CLARE, Thomas LEEDOM
  • Compounds and methods for treating oxalate-related diseases
    Patent number: 12213976
    Abstract: Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need thereof. Methods of modulating glycolate oxidase activity in a human or animal subject are also provided.
    Type: Grant
    Filed: October 12, 2022
    Date of Patent: February 4, 2025
    Assignee: OxaluRx, Inc.
    Inventors: Ayman Kabakibi, Mehmet Kahraman, Michael Clare, Thomas Leedom
  • COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES
    Publication number: 20230110495
    Abstract: Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need thereof. Methods of modulating glycolate oxidase activity in a human or animal subject are also provided.
    Type: Application
    Filed: October 12, 2022
    Publication date: April 13, 2023
    Inventors: Ayman KABAKIBI, Mehmet KAHRAMAN, Michael CLARE, Thomas LEEDOM
  • Compounds and methods for treating oxalate-related diseases
    Patent number: 11504367
    Abstract: Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need thereof. Methods of modulating glycolate oxidase activity in a human or animal subject are also provided.
    Type: Grant
    Filed: August 22, 2020
    Date of Patent: November 22, 2022
    Assignee: OxaluRx, Inc.
    Inventors: Ayman Kabakibi, Mehmet Kahraman, Michael Clare, Thomas Leedom
  • COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES
    Publication number: 20210052586
    Abstract: Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need thereof. Methods of modulating glycolate oxidase activity in a human or animal subject are also provided.
    Type: Application
    Filed: August 22, 2020
    Publication date: February 25, 2021
    Inventors: Ayman KABAKIBI, Mehmet KAHRAMAN, Michael CLARE, Thomas LEEDOM
  • BACKBONE MODIFICATIONS TO MODULATE OLIGONUCLEOTIDE TARGETING IN VIVO
    Publication number: 20070299028
    Abstract: The present invention provides antisense compounds and methods for modulating the expression of target genes expressed in the kidney. In particular, this invention provides antisense oligonucleotide compounds optimized for targeting nucleic acid molecules expressed in the kidney. Such compounds are shown herein to efficiently modulate the expression of target genes PTEN, SGLT2 and connective tissue growth factor (CTGF) in the kidney.
    Type: Application
    Filed: February 26, 2007
    Publication date: December 27, 2007
    Inventors: Andrew Siwkowski, Edward Wancewicz, Thomas Leedom, Lynnetta Watts, Mausumee Guha, Brett Monia, Richard Griffey, Richard Geary, Scott Henry, Arthur Levin
  • Modulation of SGLT2 expression
    Publication number: 20050191653
    Abstract: Compounds, compositions and methods are provided for modulating the expression of SGLT2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding SGLT2. Methods of using these compounds for modulation of SGLT2 expression and for diagnosis and treatment of diseases and conditions associated with expression of SGLT2 are provided.
    Type: Application
    Filed: November 2, 2004
    Publication date: September 1, 2005
    Inventors: Susan Freier, Edward Wancewicz, Brett Monia, Andrew Siwkowski, Lynnetta Watts, Thomas Leedom
  • Antisense oligonucleotides optimized for kidney targeting
    Publication number: 20050113326
    Abstract: The present invention provides antisense compounds and methods for modulating the expression of target genes expressed in the kidney. In particular, this invention provides antisense oligonucleotide compounds optimized for targeting nucleic acid molecules expressed in the kidney. Such compounds are shown herein to efficiently modulate the expression of target genes SGLT2 and connective tissue growth factor (CTGF) in the kidney.
    Type: Application
    Filed: September 21, 2004
    Publication date: May 26, 2005
    Inventors: Andrew Siwkowski, Edward Wancewicz, Thomas Leedom, Lynnetta Watts, Mausumee Guha, Brett Monia